StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy

StockNews.com lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from a strong-buy rating to a buy rating in a report released on Monday. A number of other equities analysts have also recently commented on the stock. Raymond James initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They […]

Related Keywords

Canada ,United States ,Mark Douglas Smith ,Raymond James ,Analyst Recommendations For Jazz Pharmaceuticals ,Jazz Pharmaceuticals Price Performance ,Nasdaq ,News Ratings For Jazz Pharmaceuticals Daily ,St Germaindj Co ,Covestor Ltd ,Jazz Pharmaceuticals Company Profile ,V Square Quantitative Management ,Royal Bank ,Securities Exchange Commission ,Needham Company ,Jazz Pharmaceuticals ,Massmutual Trust Co ,Free Report ,Moderate Buy ,Get Free Report ,Director Mark Douglas Smith ,Exchange Commission ,Square Quantitative Management ,Spire Wealth Management ,Wealth Management ,Jazz Pharmaceuticals Daily ,Nasdaq Jazz ,Jazz ,Medical ,G5087110 ,Downgrade ,Stocknews Com ,